Back
Full-text
Journal article

Intralymphatic immunotherapy.

  • Senti G Clinical Trials Center, University Hospital Zurich, Raemistrasse 100/MOU2, CH-8091 Zurich, Switzerland.
  • Kündig TM Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • 2015-03-18
Published in:
  • The World Allergy Organization journal. - 2015
Administration routes
Allergen immunotherapy
Intralympathic
Vaccination
English Gold Standard allergen-specific immunotherapy is associated with low efficacy because it requires either many subcutaneous injections of allergen or even more numerous sublingual allergen administrations to achieve amelioration of symptoms. Intralymphatic vaccination can maximize immunogenicity and hence efficacy. We and others have demonstrated that as few as three low dose intralymphatic allergen administrations are sufficient to effectively alleviate symptoms. Results of recent prospective and controlled trials suggest that this strategy may be an effective form of allergen immunotherapy.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/128954
Statistics
Document views: 40 File downloads:
  • Full-text: 0